Published in Gene Therapy Weekly, April 21st, 1997
HPV DNA can be detected in 93 percent of invasive cervical cancers; about half of these are due to HPV-16 (The International Biological Study of Cervical Cancer [IBSCC], Bosch et al., J Natl Cancer Inst, 1995;87:796-802).
HPV-16 vaccines are already in development, but researchers are hampered by lack of knowledge about the virus. The disease risk of subtype variants remains unknown, and few variants other than the European subtype have been studied at all. No one has yet shown whether...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.